NASDAQ$CTMX

CytomX Therapeutics Inc · Q1 2021 earnings

Q1 2021 earnings ·

Headline financials

Total Revenue

$16M

Previous: $49.6M-67.8%
EPS

-$0.26

Previous: $0.26-200.0%
Capital Expenditures

-$982K

Previous: -$1.05M+6.4%
Free Cash Flow

-$16.5M

Previous: $11.2M-248.2%
Net Income

-$15.6M

Previous: $12.2M-227.4%
Operating Income

-$15.6M

Previous: -$2.79M-459.5%
Gross Profit

$16M

Previous: $49.6M-67.8%

Revenue & EPS history

CytomX Therapeutics Inc · Revenue · Quarterly

$16M

Q1 2021-67.8%vs Q1 2020

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2021

Historical avgQ1 2021

+3.6%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+2.5%

Avg return

30 days after

53%

16 / 30 earnings

Positive

+129.5%

Q1 2025

Best reaction

-19.3%

Q4 2025

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-3.4%-6.3%-27.8%
Q4 2025-19.3%-34.1%-27.6%
Q3 2025-0.5%-2.6%-6.2%
Q1 2025+129.5%+118.8%+203.9%
Q3 2024+0.0%+4.0%+18.0%
Q2 2024+1.7%+0.0%+3.4%
Q1 2024+2.9%-53.6%-59.7%
Q3 2023+0.8%-7.9%+15.0%
Q2 2023-0.6%-1.2%-18.8%
Q1 2023+2.4%+6.0%+3.6%
Q3 2022-1.6%+3.2%+29.6%
Q2 2022+3.8%+1.9%-7.0%
Q1 2022-5.8%+4.1%+4.1%
Q3 2021-2.0%+14.8%+8.4%
Q2 2021+3.8%-12.0%-7.9%
Q1 2021-4.5%-4.5%-20.6%
Q3 2020+0.0%+5.7%+4.7%
Q2 2020+1.3%-6.2%-11.9%
Q1 2020+1.7%+21.5%-33.1%
Q3 2019+0.8%-9.8%+3.1%
Q2 2019+2.6%-7.3%-19.9%
Q1 2019-0.1%+7.2%+3.4%
Q3 2018-8.8%+7.3%-1.1%
Q2 2018+1.6%-4.2%-19.4%
Q1 2018+0.9%-3.6%+2.2%
Q3 2017-1.7%-1.4%+0.4%
Q2 2017+0.2%+2.6%+23.1%
Q1 2017+2.3%-0.2%-2.3%
Q3 2016-2.8%-5.7%-2.3%
Q2 2016+3.2%+10.8%+19.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro